Press Releases
2021
June 22, 2021
Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors
May 5, 2021
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors
March 8, 2021
Caribou Biosciences to Participate in Three Upcoming Investor Conferences in March
February 10, 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
February 9, 2021
Caribou Biosciences Appoints Jason O’Byrne as Chief Financial Officer
2020
November 18, 2020
Caribou Biosciences Announces Licensing Agreement for scFvs Targeting CD371 to Enable Development of Allogeneic Cell Therapies
October 7, 2020
Caribou Biosciences Co-Founder Dr. Jennifer Doudna Awarded Nobel Prize in Chemistry
September 8, 2020
Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy
May 11, 2020
Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development
May 7, 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
February 19, 2020
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA
2019
November 18, 2019
Caribou Biosciences Announces New Methods to Harness Type I CRISPR-Cas Systems for Genome Engineering in Human Cells
September 26, 2019
Caribou Biosciences Announces that JAMS panel issued Interim Award in the arbitration with Intellia Therapeutics
February 12, 2019
Caribou Biosciences Announces Expansion of Scientific Advisory Board
2018
December 12, 2018
Caribou Biosciences Appoints Dr. Natalie Sacks to Board of Directors
May 3, 2018
Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business Officer
